BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 1500019)

  • 1. A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage Ib-IIa cervical cancer patients with pelvic lymph node metastases.
    Tattersall MH; Ramirez C; Coppleson M
    Gynecol Oncol; 1992 Aug; 46(2):176-81. PubMed ID: 1500019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent chemotherapy and adjuvant extended field irradiation after radical surgery for cervical cancer patients with lymph node metastases.
    Cheng X; Cai SM; Li ZT; Wu XH; Ding YQ; Wang XE; Zang RY
    Int J Gynecol Cancer; 2008; 18(4):779-84. PubMed ID: 17944922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial.
    Curtin JP; Hoskins WJ; Venkatraman ES; Almadrones L; Podratz KC; Long H; Teneriello M; Averette HA; Sevin BU
    Gynecol Oncol; 1996 Apr; 61(1):3-10. PubMed ID: 8626113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study.
    Eddy GL; Manetta A; Alvarez RD; Williams L; Creasman WT
    Gynecol Oncol; 1995 Jun; 57(3):412-6. PubMed ID: 7774847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year survival of patients with locally advanced, stage ib-iib cervical cancer after neoadjuvant chemotherapy and radical hysterectomy.
    Hwang YY; Moon H; Cho SH; Kim KT; Moon YJ; Kim SR; Kim DS
    Gynecol Oncol; 2001 Jul; 82(1):88-93. PubMed ID: 11426967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma.
    Monk BJ; Cha DS; Walker JL; Burger RA; Ramsinghani NS; Manetta A; DiSaia PJ; Berman ML
    Gynecol Oncol; 1994 Jul; 54(1):4-9. PubMed ID: 8020837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy versus radiation therapy after radical surgery in high-risk positive node stage IB/IIA cervical cancer.
    Mossa B; Mossa S; Marziani R
    Eur J Gynaecol Oncol; 2010; 31(5):545-50. PubMed ID: 21061797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of tumor size on the prognosis of carcinoma of the uterine cervix Stage IB and IIA treated with preoperative irradiation and surgery.
    Grigsby PW; Perez CA; Chao KS; Elbendary A; Herzog TJ; Rader JS; Mutch DG
    Int J Radiat Oncol Biol Phys; 1999 Oct; 45(3):645-51. PubMed ID: 10524418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for recurrence in patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation.
    Lin HH; Cheng WF; Chan KW; Chang DY; Chen CK; Huang SC
    Obstet Gynecol; 1996 Aug; 88(2):274-9. PubMed ID: 8692515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of a failed prospective trial of adjuvant therapy after radical hysterectomy for stage Ib-IIa cervical carcinoma with pelvic node metastases.
    Lai CH; Tang SG; Chang TC; Tseng CJ; Chou HH; Huang KG; Hsueh S; Hong JH; Huang SL; Lin JD; Soong YK
    Changgeng Yi Xue Za Zhi; 1998 Sep; 21(3):291-9. PubMed ID: 9849010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy.
    Wertheim MS; Hakes TB; Daghestani AN; Nori D; Smith DH; Lewis JL
    J Clin Oncol; 1985 Jul; 3(7):912-6. PubMed ID: 2410573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of different postoperative adjuvant therapies for stage Ib-IIa cervical carcinoma with risk factors].
    Wen HW; Huang WP; Liu TY; Ma K; Tao X; Zhu LR; Liao QP
    Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):920-4. PubMed ID: 24495686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients.
    Zheng M; Huang L; Liu JH; Xiong Y; Li JD; Huang X; He L; Ren YF; Wang HY
    J Surg Oncol; 2011 Oct; 104(5):480-5. PubMed ID: 21538358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer.
    Takeshima N; Umayahara K; Fujiwara K; Hirai Y; Takizawa K; Hasumi K
    Gynecol Oncol; 2006 Nov; 103(2):618-22. PubMed ID: 16777200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical analysis of the recurrence of early stage bulky cervical carcinoma].
    Hu JL; Wu LY; Li XG; Zhang R; Li N; Yao HW
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):378-81. PubMed ID: 22883461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
    Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
    Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in patients with bulky stage IB or IIA cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy.
    Lai CH; Hsueh S; Chang TC; Tseng CJ; Huang KG; Chou HH; Chen SM; Chang MF; Shum HC
    Gynecol Oncol; 1997 Mar; 64(3):456-62. PubMed ID: 9062150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy.
    Tsai CS; Lai CH; Wang CC; Chang JT; Chang TC; Tseng CJ; Hong JH
    Gynecol Oncol; 1999 Dec; 75(3):328-33. PubMed ID: 10600284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy.
    Gadducci A; Teti G; Barsotti C; Tana R; Fanucchi A; Orlandini C; Fabrini MG; Genazzani AR
    Anticancer Res; 2010 Jan; 30(1):201-8. PubMed ID: 20150636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervical cancer: combined modality therapy.
    Grigsby PW
    Cancer J; 2001; 7 Suppl 1():S47-50. PubMed ID: 11504285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.